Skip To Content

Thought leadership on the clinical impact on workers' compensation and auto no-fault.

Recent blog posts

April 02, 2020 · From the desk of David W. Young
While there are many unknowns, Optum Workers’ Compensation and Auto No-Fault is committed to our customers, claimants and our team members. We remain fully staffed and operational and continue to ensure that the injured person is receiving the right treatment at the right time for the right duration and for the most appropriate cost. Read more...
March 23, 2020
The combination of two non-opioid analgesic medications used to treat pain and inflammation will soon be available over-the-counter (OTC), according to the U.S. Food and Drug Administration (FDA) and an announcement from GlaxoSmithKline (GSK) on March 2, 2020. Read more...
March 18, 2020 · From the desk of David W. Young
Given the recent developments and extensive news coverage about COVID-19, we understand the heightened concerns of our clients, partners and injured persons. At Optum Workers’ Comp and Auto No-Fault, our top priorities are the health and wellbeing of those we serve and the safety of those who deliver care; and we stand ready to support your needs during these challenging times.  Our dedicated employees have rigorously planned and tested our processes, systems and supply chains for business continuity, resiliency and recovery to do everything possible to support the health of those we are privileged to serve. Read more...
March 04, 2020 · Clinical Connection team
The novel coronavirus (COVID-19), that began to emerge in late 2019, has become an increasing public health concern due to its ease of person-to-person transmission. Read more...
February 27, 2020 · Clinical Connection team
Voltaren Gel 1% (diclofenac sodium topical gel) ― a common medication in workers’ compensation and auto no-fault ― will soon transition from prescription (Rx) to over-the-counter (OTC) status, according to the U.S. Food and Drug Administration (FDA). Read more...
January 16, 2020
The U.S. Food and Drug Administration (FDA) has approved a new medication to treat acute (immediate) migraine with or without aura (often described as a visual disturbance such as flashing lights) in adults. Read more...
December 17, 2019 · Clinical Connection team
On December 19, 2019, the U.S. Food and Drug Administration (FDA) issued a warning that patients with certain respiratory risk factors who are using gabapentin (Neurontin®, Gralise®, Horizant®) or pregabalin (Lyrica®, Lyrica® CR) may experience serious breathing difficulties. Read more...
     Next >>
Page 1 of 3

Subscribe today to receive our latest blogs, articles and more.

Subscribe now button

Download the latest
Pharmacy Resource Guide

Pharmacy Resource Guide